Evidence map›Paper›PMID 39349147›Full record

ArticleNeuroImage2024

Quantitative evaluation of Scout Accelerated Motion Estimation and Reduction (SAMER) MPRAGE for morphometric analysis of brain tissue in patients undergoing evaluation for memory loss.

Nelson Gil, Azadeh Tabari, Wei-Ching Lo, Bryan Clifford, Min Lang, Komal Awan, Kyla Gaudet, Daniel Nicolas Splitthoff, Daniel Polak, Stephen Cauley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nelson GilDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: nhgil@mgh.harvard.edu.
Azadeh TabariDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Wei-Ching LoSiemens Medical Solutions USA, Boston, MA, USA.
Bryan CliffordSiemens Medical Solutions USA, Boston, MA, USA.
Min LangDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Komal AwanDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Kyla GaudetDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Daniel Nicolas SplitthoffSiemens Healthineers, Erlangen, Germany.
Daniel PolakSiemens Healthineers, Erlangen, Germany.
Stephen CauleyHarvard Medical School, Boston, MA, USA; Department of Radiology, A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.
Susie Y HuangDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

Funding

Training and Dissemination CoreP41EB030006 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI Susie Yi Huang · 2020 to 2026
$10.9M
A magnetic particle imager (MPI) for functional brain imaging in humansU01EB025121 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI WALD, LAWRENCE L · 2017 to 2022
$6.1M
Toward a Validated in Vivo Imaging Marker of Axonal Damage Predictive of Progressive Disability in Multiple SclerosisR01NS118187 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, SUSIE YI · 2021 to 2025
$2.8M
Developing a validated biomarker of cortical neurodegeneration in Alzheimer's disease using high-gradient diffusion MRIR21AG085795 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, SUSIE YI · 2024 to 2025
$459k
NIA NIH HHS R21 AG085795NIBIB NIH HHS P41 EB030006NIBIB NIH HHS U01 EB025121NINDS NIH HHS R01 NS118187Siemens Healthineers
6 · The paper itself

Abstract

backgroundThree-dimensional (3D) T1-weighted MRI sequences such as the magnetization prepared rapid gradient echo (MPRAGE) sequence are important for assessing regional cortical atrophy in the clinical evaluation of dementia but have long acquisition times and are prone to motion artifact. The recently developed Scout Accelerated Motion Estimation and Reduction (SAMER) retrospective motion correction method addresses motion artifact within clinically-acceptable computation times and has been validated through qualitative evaluation in inpatient and emergency settings.

methodsWe evaluated the quantitative accuracy of morphometric analysis of SAMER motion-corrected compared to non-motion-corrected MPRAGE images by estimating cortical volume and thickness across neuroanatomical regions in two subject groups: (1) healthy volunteers and (2) patients undergoing evaluation for dementia. In part (1), we used a set of 108 MPRAGE reconstructed images derived from 12 healthy volunteers to systematically assess the effectiveness of SAMER in correcting varying degrees of motion corruption, ranging from mild to severe. In part (2), 29 patients who were scheduled for brain MRI with memory loss protocol and had motion corruption on their clinical MPRAGE scans were prospectively enrolled.

resultsIn part (1), SAMER resulted in effective correction of motion-induced cortical volume and thickness reductions. We observed systematic increases in the estimated cortical volume and thickness across all neuroanatomical regions and a relative reduction in percent error values compared to reference standard scans of up to 66 % for the cerebral white matter volume. In part (2), SAMER resulted in statistically significant volume increases across anatomical regions, with the most pronounced increases seen in the parietal and temporal lobes, and general reductions in percent error relative to reference standard clinical scans.

conclusionSAMER improves the accuracy of morphometry through systematic increases and recovery of the estimated cortical volume and cortical thickness following motion correction, which may affect the evaluation of regional cortical atrophy in patients undergoing evaluation for dementia.

Indexed as

ArtifactsBrainMagnetic Resonance ImagingAdultAgedAged, 80 and overDementiaFemaleHumansImage Processing, Computer-AssistedMaleMemory DisordersMiddle AgedMotionMemory lossMorphometryMotion correctionVolumetric brain MRI

Identifiers

PMID39349147
PMCPMC11498920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.